Items Tagged ‘gastroesophageal junction cancer’

February 13, 2018

Keytruda Promising in PD-L1 Esophageal Cancer


CancerConnect News: The checkpoint inhibitor Keytruda (pembrolizumab) has been reported to produce an overall response rate of 30% in patients with PD-L1–positive, advanced esophageal cancer.1 About Keytruda Keytruda is a monoclonal antibody that helps to restore the body’s immune system in fighting cancer. It creates its anti-cancer effects by blocking a specific protein used by cancer […]

View full entry

Tags: checkpoint inhibitor, Esophageal Cancer, gastroesophageal junction cancer, immunotherapy, keytruda, News, pembrolizumab, Precision Cancer Medicine